Plakous Therapeutics, a biotech start-up in Winston-Salem, is pioneering regenerative healing from traditional stem cell therapies. Using proteins from the human placenta, the company is developing medicine to combat necrotizing enterocolitis, also known as NEC. NEC is a condition that affects premature babies weighing less than three pounds and between 22 to 33 weeks of age. Rob Boyce, CEO of Plakous Therapeutics, joins us to discuss product development and his career path from naval aviation and marketing to biotech.